Hepatitis B is a chronic infection affecting roughly 254 million people worldwide and causing about 1.1 million deaths each year, mainly from cirrhosis and liver cancer. “I call hepatitis B the most frequent neglected disease in the world,” said Protzer, who is leading an international team of researchers developing a new vaccine for people living with chronic hepatitis B. While conventional hepatitis B vaccines prevent infection, this therapeutic vaccine is intended for people who are already chronically infected.“ Precision medicine for hepatitis B will be a must to optimise the hepatitis B virus cure rates.Professor Fabien Zoulim, IP-cure-BRecognising that no single approach is likely to solve the problem alone, the TherVacB and IP‑cure‑B teams teamed up in 2023. “Precision medicine for hepatitis B will be a must to optimise the hepatitis B virus cure rates.”